Stay up-to-date with the latest information from Quadriga
February 14, 2023
Quadriga BioSciences Announces Dosing of First Subject in Phase 2 Study Evaluating QBS72S For Glioblastoma
October 25, 2022
Quadriga BioSciences Announces Completion of Enrollment in Phase 1 Study of QBS72S for Solid Tumors
July 23, 2020
Quadriga Initiates Clinical Trial of Innovative, Targeted Treatment for Brain Cancers
October 10, 2017
Quadriga Wins $2M Phase II SBIR Grant for the Treatment of Glioblastoma Multiforme
Posters & Publications
A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma.
Ozawa T, et al. Cureus (2021) 13(8): e17595.
A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer.
Deng J, et al. MCT First Disclosures Molecular Cancer Therapeutics (2021) 20(11): 2110–2116.
A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Breast Cancer Leptomeningeal Metastases
Presented at: SNO Conference on Brain Metastases, 2019
Hijacking Myeloma Metabolism to Target Cytotoxic Chemotherapy to Malignant Plasma Cells with Decreased Bone Marrow Toxicity
Presented at: American Society of Hematology, 2017
A Novel BBB-permeable Chemotherapeutic Agent for the Treatment of Glioblastoma
Presented at: Society for NeuroOncology (SNO), 2016
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) ClinicalTrials.gov Identifier: NCT02977780
Study Assessing QBS72S For Treating Brain Metastases of Triple Negative Breast Cancer. ClinicalTrials.gov Identifier: NCT05305365
A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma. ClinicalTrials.gov Identifier: NCT04430842